AR008880A1 - Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos. - Google Patents
Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos.Info
- Publication number
- AR008880A1 AR008880A1 ARP970104586A ARP970104586A AR008880A1 AR 008880 A1 AR008880 A1 AR 008880A1 AR P970104586 A ARP970104586 A AR P970104586A AR P970104586 A ARP970104586 A AR P970104586A AR 008880 A1 AR008880 A1 AR 008880A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- pharmaceutical composition
- disease
- alkyl
- ilo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de ácido 2-amino carboxílico sustituido con (3-alcoxiisoxazol-4- -ilo) o análogos de azufre de los mismos que tienen la formula general I o II,en donde R1 es hidrogeno, alquilo, alquenilo, alquinilo, cicloalq(en)ilo, ciloalq(en)il-a lq(en/in)il- alq(en/in)ilo o fenil - alq(en/in)ilooptativamente sustituido; A es un enlace o un grupo espaciador hidrocarburo; B es un grupo -CRa (NRbRc)-COOR5 en donde Ra - Rc son independdientementehidrogeno o alquilo y R5 se define como R1 opiva loiloximetilo, o B es un grupo de formula III, en donde R2, R3 y R4 son independientemente seleccionados entrehidrogeno, un grupo hidrocarburo no aromático, fenil y tienil-alquilo y un grupo heteroalifático, o R3 y R4 están conectaods,formando de ese modo ungrupo alquileno, alquenileno o alquinileno, o R4 y R2 están conectados, formando de ese modo un grupo alquenileno o alquinileno optativamentesustituido con hidroxi o metilo, o para formar CH2-O-CH2; E es COOR6 donde R6 se defi ne como R5, o E es un tetrazolilo o triazolilo; X es O o S; e Y es O oS; son aminoácido excitatorio (EAA), en particular ligandos de receptores AMPA y/o NMDA, utiles en el tratamiento de la isquemia cerebral, enfermedad deHuntington,trastornos epil éptidos, enfermedad de Parkinson, enfermedad de Alzheimer, esquizofrenia, dolor, depresion y ansiedad. Se provee también unacomposicion farmacéutica que los comprende y un uso de los mismos para preparar una composicionfarmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK109296 | 1996-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008880A1 true AR008880A1 (es) | 2000-02-23 |
Family
ID=8100908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104586A AR008880A1 (es) | 1996-10-04 | 1997-10-03 | Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6200999B1 (es) |
| EP (1) | EP0934286B1 (es) |
| JP (1) | JP2001501630A (es) |
| KR (1) | KR20000048908A (es) |
| CN (1) | CN1238766A (es) |
| AR (1) | AR008880A1 (es) |
| AT (1) | ATE230734T1 (es) |
| AU (1) | AU733004B2 (es) |
| BG (1) | BG103348A (es) |
| BR (1) | BR9712198A (es) |
| CA (1) | CA2268028C (es) |
| CZ (1) | CZ116899A3 (es) |
| DE (1) | DE69718338T2 (es) |
| EA (1) | EA001625B1 (es) |
| ES (1) | ES2189978T3 (es) |
| HU (1) | HUP0000084A3 (es) |
| IL (1) | IL129135A0 (es) |
| IS (1) | IS5009A (es) |
| NO (1) | NO312961B1 (es) |
| NZ (1) | NZ334798A (es) |
| PL (1) | PL332553A1 (es) |
| SK (1) | SK42899A3 (es) |
| TR (1) | TR199900724T2 (es) |
| UA (1) | UA52698C2 (es) |
| WO (1) | WO1998015542A1 (es) |
| ZA (1) | ZA978877B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73749C2 (en) * | 1999-11-01 | 2005-09-15 | Diarylenines | |
| ATE335737T1 (de) * | 2000-09-15 | 2006-09-15 | Vertex Pharma | Isoxazole und ihre verwendung als erk-inhibitoren |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| MXPA05010760A (es) | 2003-04-09 | 2005-12-12 | Wyeth Corp | Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda). |
| GT200400213A (es) | 2003-10-22 | 2007-09-05 | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
| AU2006301376A1 (en) * | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Isoxazole derivatives |
| WO2009092324A1 (en) * | 2008-01-16 | 2009-07-30 | Hong Kong University Of Science And Technology | Oxazolidine derivatives as nmda antagonists |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| TW201609719A (zh) | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| WO2017126197A1 (ja) * | 2016-01-21 | 2017-07-27 | アグロカネショウ株式会社 | ２－アミノニコチン酸ベンジルエステル誘導体の製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0456519T3 (da) | 1990-05-11 | 1994-11-07 | Sankyo Co | Piperidyloxy- og quinuclidinyloxyisoxazolderivater, deres fremstilling og deres terapeutiske anvendelse |
| JPH08502508A (ja) | 1992-10-23 | 1996-03-19 | メルク シヤープ エンド ドーム リミテツド | ドーパミンレセプターサブタイプリガンド |
| DK124393D0 (da) * | 1993-11-03 | 1993-11-03 | Lundbeck & Co As H | Compounds |
-
1997
- 1997-03-10 UA UA99042300A patent/UA52698C2/uk unknown
- 1997-10-03 EA EA199900358A patent/EA001625B1/ru not_active IP Right Cessation
- 1997-10-03 ZA ZA9708877A patent/ZA978877B/xx unknown
- 1997-10-03 IL IL12913597A patent/IL129135A0/xx unknown
- 1997-10-03 BR BR9712198-3A patent/BR9712198A/pt unknown
- 1997-10-03 CZ CZ991168A patent/CZ116899A3/cs unknown
- 1997-10-03 WO PCT/DK1997/000426 patent/WO1998015542A1/en not_active Application Discontinuation
- 1997-10-03 HU HU0000084A patent/HUP0000084A3/hu unknown
- 1997-10-03 AU AU44517/97A patent/AU733004B2/en not_active Ceased
- 1997-10-03 NZ NZ334798A patent/NZ334798A/en unknown
- 1997-10-03 PL PL97332553A patent/PL332553A1/xx unknown
- 1997-10-03 TR TR1999/00724T patent/TR199900724T2/xx unknown
- 1997-10-03 CA CA002268028A patent/CA2268028C/en not_active Expired - Fee Related
- 1997-10-03 CN CN97180167A patent/CN1238766A/zh active Pending
- 1997-10-03 DE DE69718338T patent/DE69718338T2/de not_active Expired - Fee Related
- 1997-10-03 AR ARP970104586A patent/AR008880A1/es not_active Application Discontinuation
- 1997-10-03 JP JP10517096A patent/JP2001501630A/ja active Pending
- 1997-10-03 ES ES97942821T patent/ES2189978T3/es not_active Expired - Lifetime
- 1997-10-03 AT AT97942821T patent/ATE230734T1/de not_active IP Right Cessation
- 1997-10-03 US US09/269,356 patent/US6200999B1/en not_active Expired - Fee Related
- 1997-10-03 KR KR1019990702938A patent/KR20000048908A/ko not_active Application Discontinuation
- 1997-10-03 EP EP97942821A patent/EP0934286B1/en not_active Expired - Lifetime
- 1997-10-03 SK SK428-99A patent/SK42899A3/sk unknown
-
1999
- 1999-03-20 BG BG103348A patent/BG103348A/xx unknown
- 1999-03-23 IS IS5009A patent/IS5009A/is unknown
- 1999-03-30 NO NO19991561A patent/NO312961B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998015542A1 (en) | 1998-04-16 |
| ATE230734T1 (de) | 2003-01-15 |
| EP0934286A1 (en) | 1999-08-11 |
| EA199900358A1 (ru) | 1999-10-28 |
| NZ334798A (en) | 2000-06-23 |
| NO991561D0 (no) | 1999-03-30 |
| SK42899A3 (en) | 1999-08-06 |
| CN1238766A (zh) | 1999-12-15 |
| HUP0000084A3 (en) | 2001-12-28 |
| HUP0000084A2 (hu) | 2000-06-28 |
| DE69718338D1 (de) | 2003-02-13 |
| EP0934286B1 (en) | 2003-01-08 |
| CA2268028A1 (en) | 1998-04-16 |
| UA52698C2 (uk) | 2003-01-15 |
| NO312961B1 (no) | 2002-07-22 |
| US6200999B1 (en) | 2001-03-13 |
| AU4451797A (en) | 1998-05-05 |
| CZ116899A3 (cs) | 1999-09-15 |
| TR199900724T2 (xx) | 1999-06-21 |
| AU733004B2 (en) | 2001-05-03 |
| BG103348A (en) | 1999-11-30 |
| DE69718338T2 (de) | 2003-10-16 |
| NO991561L (no) | 1999-06-04 |
| IL129135A0 (en) | 2000-02-17 |
| KR20000048908A (ko) | 2000-07-25 |
| ES2189978T3 (es) | 2003-07-16 |
| BR9712198A (pt) | 1999-08-31 |
| EA001625B1 (ru) | 2001-06-25 |
| PL332553A1 (en) | 1999-09-13 |
| ZA978877B (en) | 1998-04-17 |
| CA2268028C (en) | 2003-03-18 |
| IS5009A (is) | 1999-03-23 |
| JP2001501630A (ja) | 2001-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008880A1 (es) | Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos. | |
| BR0113776A (pt) | Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição | |
| BR0311558A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica | |
| HUP0100266A2 (hu) | NMDA-receptor-antagonista hatású 1-aminoalkilciklohexánszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és előállításaik | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| PT99569A (pt) | Processo para a preparacao de novos derivados de eritromicina e de composicoes farmaceuticas que os contem | |
| DE60234092D1 (de) | Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren | |
| BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
| BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
| BRPI0313477B8 (pt) | derivados de purina, composição farmacêutica que os compreende, seu processo de preparação e uso | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| ATE410412T1 (de) | Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen | |
| PT93263A (pt) | Processo para a preparacao de 19-nor esteroides contendo na posicao 11-beta umacadeia carbonada possuindo uma funcao amida ou carbamato | |
| BR9812236A (pt) | Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit | |
| KR900004659A (ko) | α,α-이치환 N- 시클로알킬알킬 벤질아민, 이들의 제조 방법, 의약품으로서 이들의 용도 및 이들의 합성 중간체 | |
| PT919541E (pt) | Novos compostos naftalenicos processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
| GR3023107T3 (en) | New 19-nor 11-beta-phenoxysulfonamide or 11-beta-phenoxyalkylsulfonylurea steriod derivatives, a process and intermediates for their production and their use as medicaments and pharmaceuticals containing them. | |
| KR910000630A (ko) | 할로겐 치환 디페닐 설파이드, 이의 제조방법 및 우울증 치료제로서의 용도 | |
| BR9815920A (pt) | Compostos aza-heterocìclicos usados para tratar distúrbios neurológicos e queda de cabelo | |
| BR9808042A (pt) | Composto, composição farmacêutica, e, processo para preparação de compostos. | |
| KR910005873A (ko) | 항프로게스테론양 화합물의 신규 용도 | |
| RU2003102436A (ru) | Нейропротекторные 7-бета-гидроксистероиды | |
| HUP0102532A2 (hu) | Idegrendszeri betegségek és hajhullás kezelésére szolgáló aza-heterociklusos vegyületek és eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| PT99864A (pt) | Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato | |
| BR1100306A (pt) | Compostos, composições farmacêuticas, uso de um composto e processo para preparação de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |